Related Experiment Videos
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Jurriën M ten Berg1, HW Thijs Plokker, Freek WA Verheugt
1Department of Cardiology, St Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands. jurtenberg@wxs.nl
Insights
This review covers antiplatelet and anticoagulant therapies for preventing thrombosis after percutaneous coronary intervention. It focuses on commonly used agents to manage acute vessel closure post-angioplasty and stenting.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Thrombosis is a significant cause of acute vessel closure following coronary balloon angioplasty and stenting.
- Effective prevention strategies are crucial to minimize complications after percutaneous coronary intervention (PCI).
Purpose of the Study:
- To review the role of antiplatelet and anticoagulant therapies in preventing early thrombotic complications after PCI.
- To focus on routinely available and commonly used therapeutic agents.
Main Methods:
- Literature review of antiplatelet and anticoagulant therapies.
- Analysis of agents used in preventing thrombosis post-PCI.
- Focus on clinical practice guidelines and common pharmacopeia.
Main Results:
- Antiplatelet agents are fundamental in preventing stent thrombosis and restenosis.
- Anticoagulant therapy plays a critical role during the PCI procedure itself.
- Combination therapy strategies are often employed to optimize thrombotic risk reduction.
Conclusions:
- Appropriate antiplatelet and anticoagulant therapy is essential for managing thrombotic risks after PCI.
- The selection of agents should be guided by patient-specific factors and procedural characteristics.
- Ongoing research aims to refine therapeutic regimens for improved patient outcomes.
Abstract:
Thrombosis plays a major role in acute vessel closure both after coronary balloon angioplasty and after stenting. This review will address the role of antiplatelet and anticoagulant therapy in preventing early thrombotic complications after percutaneous coronary intervention. The focus will be on agents that are routinely available and commonly used.